Tinto, H. et al. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45 (2015).
Organization, W. H. Malaria vaccines (RTS,S and R21), https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccine (2024).
Birkett, A., Miller, R. S. & Soisson, L. A. The Importance of Exercising Caution When Comparing Results from Malaria Vaccines Administered on the EPI Schedule and on a Seasonal Schedule. Am. J. Trop. Med Hyg. 107, 1356–1356 (2022).
Kurtovic, L. et al. Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial. Lancet Microbe 5, 100898 (2024).
Shim, E. & Galvani, A. P. Distinguishing vaccine efficacy and effectiveness. Vaccine 30, 6700–6705 (2012).
Vaccine efficacy, effectiveness and protection, https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection (2025).
Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet 403, 533–544 (2024).
Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet 397, 1809–1818 (2021).
WHO. (2021).
Moita, D. & Prudencio, M. Whole-sporozoite malaria vaccines: where we are, where we are going. EMBO Mol. Med 16, 2279–2289 (2024).
Stanisic, D. I., McCarthy, J. S. & Good, M. F. Controlled Human Malaria Infection: Applications, Advances, and Challenges. Infect Immun 86 https://doi.org/10.1128/IAI.00479-17 (2018).
Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight 2, 1–14 (2017).
Jongo, S. A. et al. Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults. Clin. Infect. Dis. 71, 2849–2857 (2020).
Jongo, S. A. et al. Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults. Am. J. Trop. Med Hyg. 106, 1215–1226 (2022).
Jongo, S. A. et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am. J. Trop. Med Hyg. 99, 338–349 (2018).
Roestenberg, M. et al. Protection against a Malaria Challenge by Sporozoite Inoculation. N. Engl. J. Med 361, 468–477 (2009).
Mordmuller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445–449 (2017).
Khan, S. M., Janse, C. J., Kappe, S. H. & Mikolajczak, S. A. Genetic engineering of attenuated malaria parasites for vaccination. Curr. Opin. Biotechnol. 23, 908–916 (2012).
Mueller, A. K., Labaied, M., Kappe, S. H. I. & Matuschewski, K. Genetically modified parasites as a protective experimental malaria vaccine. Nature 433, 164–167 (2005).
Mueller, A. K. et al. Liver stage developmental arrest by depletion of a protein at the parasite-host interface. P Natl Acad. Sci. USA 102, 3022–3027 (2005).
Kaiser, K., Matuschewski, K., Camargo, N., Ross, J. & Kappe, S. H. Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins. Mol. Microbiol 51, 1221–1232 (2004).
Lindner, S. E. et al. Transcriptomics and proteomics reveal two waves of translational repression during the maturation of malaria parasite sporozoites. Nat. Commun. 10, 4964 (2019).
Tarun, A. S. et al. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J. Infect. Dis. 196, 608–616 (2007).
Jobe, O. et al. Genetically-attenuated liver-stages induce sterile protracted protection that is mediated by MHC class I-dependent IFN-γ producing CD8+ T cells. Am. J. Trop. Med Hyg. 77, 90–90 (2007).
Mackellar, D. C. et al. Plasmodium falciparum PF10_0164 (ETRAMP10.3) is an essential parasitophorous vacuole and exported protein in blood stages. Eukaryot. Cell 9, 784–794 (2010).
Goswami, D. et al. A Plasmodium falciparum ATP-binding cassette transporter is essential for liver stage entry into schizogony. Iscience 25, 104224 (2022).
Vaughan, A. M. et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 11, 506–520 (2009).
Butler, N. S. et al. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9, 451–462 (2011).
Yu, M. et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 4, 567–578 (2008).
van Schaijk, B. C. et al. Type II fatty acid biosynthesis is essential for Plasmodium falciparum sporozoite development in the midgut of Anopheles mosquitoes. Eukaryot. Cell 13, 550–559 (2014).
Labaied, M. et al. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect. Immun. 75, 3758–3768 (2007).
van Schaijk, B. C. et al. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS One 3, e3549 (2008).
van Dijk, M. R. et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc. Natl Acad. Sci. USA 102, 12194–12199 (2005).
Annoura, T. et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 30, 2662–2670 (2012).
Spring, M. et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 31, 4975–4983 (2013).
VanBuskirk, K. M. et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc. Natl Acad. Sci. USA 106, 13004–13009 (2009).
O’Neill, M. T., Phuong, T., Healer, J., Richard, D. & Cowman, A. F. Gene deletion from Plasmodium falciparum using FLP and Cre recombinases: implications for applied site-specific recombination. Int J. Parasitol. 41, 117–123 (2011).
Mikolajczak, S. A. et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol. Ther. 22, 1707–1715 (2014).
Aly, A. S. I., Lindner, S. E., MacKellar, D. C., Peng, X. X. & Kappe, S. H. I. SAP1 is a critical post-transcriptional regulator of infectivity in malaria parasite sporozoite stages. Mol. Microbiol 79, 929–939 (2011).
Aly, A. S. I. et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol. Microbiol 69, 152–163 (2008).
Kublin, J. G. et al. Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci Transl Med 9 https://doi.org/10.1126/scitranslmed.aad9099 (2017).
Murphy, S. C. et al. A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection. Sci Transl Med 14 https://doi.org/10.1126/scitranslmed.abn9709 (2022).
Annoura, T. et al. Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development. Faseb J. 28, 2158–2170 (2014).
van Schaijk, B. C. et al. A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. Elife 3, 1–18 (2014).
Roestenberg, M. et al. A double-blind, placebo-controlled phase 1/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci. Transl. Med 12, 1–9 (2020).
Langenberg, M. C. C., Dekkers, O. M. & Roestenberg, M. Are placebo controls necessary in controlled human infection trials for vaccines?. Lancet Infect. Dis. 20, e69–e74 (2020).
Dankwa, D. A., Davis, M. J., Kappe, S. H. I. & Vaughan, A. M. A Plasmodium yoelii Mei2-Like RNA Binding Protein Is Essential for Completion of Liver Stage Schizogony. Infect. Immun. 84, 1336–1345 (2016).
Franke-Fayard, B. et al. Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver. Npj Vaccines 7, 1–17 (2022).
Vaughan, A. M. et al. A Plasmodium Parasite with Complete Late Liver Stage Arrest Protects against Preerythrocytic and Erythrocytic Stage Infection in Mice. Infect. Immun. 86, 1–18 (2018).
Goswami, D. et al. A replication-competent late liver stage-attenuated human malaria parasite. JCI Insight 5, 1–19 (2020).
Lamers, O. A. C. et al. Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite. N. Engl. J. Med 391, 1913–1923 (2024).
Roozen, G. V. T. et al. Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial. Nat. Med 31, 218–222 (2025).
Goswami, D. et al. A conserved nuclear protein is critical for late liver stage development. Commun Biol 7 https://doi.org/10.1038/s42003-024-07063-y (2024).
Goswami, D. et al. A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion. EMBO Mol. Med 16, 723–754 (2024).
Cockburn, I. A. & Seder, R. A. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat. Immunol. 19, 1199–1211 (2018).
Mura, M. et al. Immunoprofiling Identifies Functional B and T Cell Subsets Induced by an Attenuated Whole Parasite Malaria Vaccine as Correlates of Sterile Immunity. Vaccines (Basel) 10 https://doi.org/10.3390/vaccines10010124 (2022).
Murphy, S. C. et al. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog. 17, e1009594 (2021).
Bijker, E. M. et al. Cytotoxic Markers Associate With Protection Against Malaria in Human Volunteers Immunized With Plasmodium falciparum Sporozoites. J. Infect. Dis. 210, 1605–1615 (2014).
Colstrup, E. et al. Correlative humoral and cellular immunity to genetically attenuated malaria parasites in humans. iScience 28, 112589 (2025).
Rogers, K. J., Vijay, R. & Butler, N. S. Anti-malarial humoral immunity: the long and short of it. Microbes Infect. 4-5, 104807 (2021).
Singer, M., Kanatani, S., Castillo, S. G., Frischknecht, F. & Sinnis, P. The Plasmodium circumsporozoite protein. Trends Parasitol. 40, 1124–1134 (2024).
Guttery, D. S., Zeeshan, M., Holder, A. A., Tromer, E. C. & Tewari, R. Meiosis in Plasmodium: how does it work?. Trends Parasitol. 39, 812–821 (2023).
Midtvedt, T. Antibiotic resistance and genetically modified plants. Microb Ecol Health Dis 25 https://doi.org/10.3402/mehd.v25.25918 (2014).
Sakurai, F., Tachibana, M. & Mizuguchi, H. Adenovirus vector-based vaccine for infectious diseases. Drug Metab. Pharmacokinet. 42, 100432 (2022).
van Dorst, M. et al. Immunological factors linked to geographical variation in vaccine responses. Nat Rev Immunol https://doi.org/10.1038/s41577-023-00941-2 (2023).
Reuling, I. J. et al. An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria. Sci Transl Med 12 https://doi.org/10.1126/scitranslmed.aay2 (2020).
Rich, S. M. & Ayala, F. J. Population structure and recent evolution of Plasmodium falciparum. Proc. Natl Acad. Sci. USA 97, 6994–7001 (2000).
Roestenberg, M. et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377, 1770–1776 (2011).
Blight, J. et al. Dissection-independent production of Plasmodium sporozoites from whole mosquitoes. Life Sci Alliance 4 https://doi.org/10.26508/lsa.202101094 (2021).
Eappen, A. G. et al. In vitro production of infectious Plasmodium falciparum sporozoites. Nature 612, 534–539 (2022).
Richie, T. L. et al. Sporozoite immunization: Innovative Translational Science to Support the Fight against malaria. Expert Rev. Vaccines 22, 964–1007 (2023).
Ishizuka, A. S. et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat. Med 22, 614–623 (2016).
Organization, W. H. (ed World Health Organization) (Geneva, 2022).
Pohl, K. & Cockburn, I. A. Innate immunity to malaria: The good, the bad and the unknown. Front Immunol. 13, 914598 (2022).
Sinnis, P. & Zavala, F. The skin: where malaria infection and the host immune response begin. Semin Immunopathol. 34, 787–792 (2012).
Chakravarty, S. et al. CD8+ T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes. Nat. Med 13, 1035–1041 (2007).
